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Graphene based nanomaterials are being used experimentally to deliver therapeutic agents to cells or tis-
sues both in vitro and in vivo. However, substantial challenges remain before moving to safe and effective
use in humans. In particular, it is recognised that graphene molecules undergo complex interactions with
solutes, proteins or cellular systems within the body, and that these interactions impact significantly on
the behaviour or toxicity of the molecule. Approaches to overcome these problems include modification
of the graphene or its combination with other molecules to accentuate favourable characteristics or mod-
ify adverse interactions. This has led to an emerging role for graphene as one part of highly-tailored mul-
tifunctional delivery vehicles. This review examines the knowledge that underpins present approaches to
exploit graphene in therapeutics delivery, discussing both favourable and unfavourable aspects of gra-
phene behaviour in biological systems and how these may be modified; then considers the present place
of the molecule and the challenges for its further development.
 2016 The Authors. Published by Elsevier B.V. This is an open access articleunder the CCBY license (http://
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Since the isolation of graphene in 2004, potential uses of the
material have expanded rapidly, and a wide range of biomedical
applications are now proposed [1–23]. In this review, the physical
and chemical properties of what will be referred to as the graphene
family of nanomaterials (GFNs) [24] will be reviewed in the context
of their potential role in therapeutics delivery – which includes
drugs, biopharmaceuticals and genetic material.
The use of graphene in therapeutics delivery is based upon its
particular properties. Its high surface-area to volume ratio, pol-
yaromatic structure and the ease with which various forms can
be functionalised offers capacity and flexibility for cargo loading,
transport and targeting to tissues. Additionally, the ability to com-
bine hydrophilic and hydrophobic regions on the surface of GFN
flakes supports both their solubility within aqueous environments
and their subsequent interaction with lipids in cell membranes.
However, it is also recognised that graphene may have potential
adverse interactions within biological environments that are
highly relevant to biomedical applications. In particular, interac-
tions between graphene and protein elements in biological fluids
may significantly affect the physical properties of the molecule,
potentially inducing damaging responses by the host immune sys-
tem, while the membrane interactions and chemical properties of
graphene have the potential to cause direct toxicity to target cells
or to normal ‘‘bystander cells”.
The review examines those qualities of GFNs that may make
them attractive as therapeutics delivery vehicles, before consider-
ing how the varied properties of different graphene forms may
affect their performance. Present and possible future applications
in drug delivery are then considered.sp2 hybridization in graphene and other carbon allotropes. The honeycomb stru
n their constituent carbon atoms; graphene is often described as the structural p2. Properties of graphene
2.1. The graphene family of nanomaterials
Graphene was first isolated using mechanical exfoliation in the
now famous ‘‘scotch-tape” method [25] and is the first truly two-
dimensional material. Each carbon atom of pristine graphene is
bound to three others in a flat structure (sp2 hybridised). This
structure is the basis of many carbon materials, from graphite to
carbon nanotubes (CNTs) and fullerenes, and underlies the distinc-
tive honeycomb lattice structure of the molecule [16,28] (Fig. 1).
The benzene-like structure of the hexagonal components of the lat-
tice allows it to be thought of as a giant aromatic poly-molecule
[16]. Even without further functionalisation, this structure confers
properties that are useful in therapeutics delivery: aromatic mole-
cules may bind to graphene through non-covalent interactions
between their carbon rings (p–p stacking), and the large relative
surface-area of the 2D geometry permits a single graphene flake
to be decorated with a raft of different aromatic groups [26]. For
pristine graphene, p–p stacking and hydrophobic interactions are
the major source of binding for drugs and other molecules; how-
ever, for other graphene forms the additional presence of chemical
functional groups provides a greater range of possible interactions
(Fig. 3) [26,27].
2.2. Structural features and solubility of graphene
For use in therapeutics delivery, GFN flakes must be dispersed
within biological fluids. In its pristine form graphene is hydropho-
bic; therefore, solubilisation is achieved through exfoliation of gra-
phite layers in the presence of a non-polar solvent or surfactantscture recognisable in the above materials derives from the sp2 hybridized bonds
recursor to graphite, CNTs and fullerenes.
Fig. 2. Graphene solubilised using surfactant molecules; the hydrophobic regions
cover most of the graphene flake surface, while the hydrophilic tail regions stretch
out into the aqueous solution in which the flakes are suspended. The resultant
flake’s size and geometry will be significantly changed compared to a single bare
graphene sheet.
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chemical properties that include high electrical conductivity, low
defect density, and sharp edges, but the graphene is generally very
polydisperse, both in terms of the lateral dimensions of the flakes
and the number of layers contained. To produce more uniform
samples requires additional techniques such as centrifugation sec-
tioning. Moreover, where surfactant is used, the majority of the
polyaromatic graphene-surface becomes covered by surfactant
molecules, potentially causing steric interference with other func-Fig. 3. Commonly used graphene forms. Pristine graphene is hydrophobic and so is ofte
functional groups. Graphene oxide is quite easy to prepare and so is often the precurso
pristine graphene. Graphene nanoribbons are often prepared by ‘unzipping’ carbon nan
aspect ratio is one of the physicochemical properties of graphene that changes the behational molecules and changing the geometry of the flakes by caus-
ing them to become thicker (Fig. 2). Similarly, residual molecules
from non-polar solvents must be removed when transferring the
flakes from that solvent into water, and a method of solubilising
the flakes in water must still be found. Finally, both surfactants
and residual non-polar solvent molecules adsorbed on the flake
surface may contribute significantly to the toxicity of the
preparation.
For these reasons, the introduction of pristine graphene in
biomedical applications has been relatively limited, and alternative
graphene forms have been preferred.
At present the most common preparation used is graphene
oxide (GO). This preference derives in part from its favourable sol-
ubility, which is in turn due to its surface chemistry (for a detailed
account see [27,29]). In brief, GO is predominantly prepared using
a standard or modified Hummers’ method, employing prolonged
exposure to strong oxidants such as sulphuric acid, sodium nitrate
and potassium permanganate, applied to bulk graphite, where the
oxidation also aids the exfoliation of the graphite [27,30]. The
chemical characteristics of the GO flakes are most commonly
described by the Lerf–Klinowski model [27] (Fig. 3). That model
considers the GO flake to be comprised of a typical flat sp2 bonded
honeycomb lattice with occasional defects, interrupted by sp3
bonds that allow epoxides and alcohols to project from the planar
surface, while flake edges are populated with carboxylic acids
(Fig. 3). An alternative recent model agrees that oxygenated func-
tional groups (mostly carboxylic acids) again predominantly occur
on the edges of the flake, but suggests that the surface of the GO isn solubilised using the Hummer’s method so that it is decorated with oxygenated
r to other functionalised GFNs, or reduced to prepare a material that approximates
otubes, resulting in graphene with a very high aspect ratio. It has been shown that
viour of cells to which they are exposed.
Fig. 4. GO loading and functionalisation: One of the benefits of using graphene oxide is the combination of a polyaromatic basal plane and the functional groups that extend
from it. Once GO has been prepared, other molecules may be easily attached - hydrophobically, electrostatically, via p–p interactions or covalently; alternately, the functional
groups may be chemically altered. The figure illustrates some of the myriad cargoes that have been loaded onto GO/functionalised graphene using the above techniques.
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(oxidative debris) which effectively act as stabilising agents, solu-
bilising the flakes in water [29]. Both models are supported by
results of high-resolution transmission electron microscopy
(HRTEM) [31].
2.3. Graphene as a therapeutics delivery vehicle
An ideal delivery vehicle will target therapeutic agents to their
site of action and protect them from degradation, thereby reducing
off-target effects (OTEs) and dilution, and potentially increasing
efficacy [32–36]. This requires a stable and inert vehicle whose
physicochemical properties permit its transport through complex
physiological environments, while specific characteristics ensure
cell-specific uptake and delivery [35,36]. Present trends favour
highly tailored nanoparticles with control of each physicochemical
property, from size, shape and zeta potential, through to nanoscale
roughness.
In these respects, graphene may provide advantages over other
carbon nanomaterials. GFNs may have lower toxicity [37–39], and
highly flexible physicochemical properties that allow the different
functional groups of the molecule to be modified and perform a
range of different tasks [10,15,16,40–43] (Fig. 4). Many applica-
tions employ GO prepared by Hummer’s method. The GO formed
by this method retains many of the useful structural features of
pristine graphene, including low dimensionality and the retention
of isolated patches of the honeycomb structure that allow the
attachment of water-insoluble drugs. The oxygenated functional
groups including hydroxyls, epoxides and carboxyls render the
material inherently hydrophilic reducing the need for additionalsolubilisation, and provide opportunity to bind additional func-
tional molecules through covalent bonding or electrostatic interac-
tions [15,26,27,44] (see Fig. 4). This functional flexibility is central
to the role of GO in therapeutics delivery. However, this same flex-
ibility also introduces a significant complexity: It is recognised that
GO prepared using similar techniques by different laboratories
may contain graphene flakes of polydisperse dimensions and layer
number, and this may result in the reporting of contradictory
results in apparently comparable studies [24,45]. Furthermore, full
oxygenation of the graphene lattice is thermodynamically unfa-
vourable; therefore, GO is heterogeneous in its surface chemistry
and functionalisation may be subtly different between samples
[27,31]. Finally, during the design of functionalised graphene, any
modification made to the flake structure potentially alters other
intrinsic properties, and may cause otherwise desirable features
to become lost or masked as the modified nanoparticle effectively
becomes a new material [36,46]. For instance, the addition of large
polymers will increase the thickness of graphene flakes and may
decrease their lateral sizes [47], producing a more spherical or
globular nanoparticle, rather than the 2D geometry of unmodified
graphene.
Despite improved understanding of the molecule therefore,
predicting and controlling the behaviour of graphene in different
environments remains a substantial challenge for investigators. To
address these issues, methods are being developed to produce
highly purified GO suspensions with increased biocompatibility
and reduced polydispersity, together with the development of
detailed protocols that describe the preparation of GO nanocompos-
ites for biomedical applications [37,48]. In this review we have,
where possible, sought to identify sources for any apparent
Fig. 5. Schematic of the formation of the protein corona about a flake of graphene (Vroman model). 1. Initially the soft corona is formed, made up of abundant proteins with
high dissociation constants, i.e. are weakly bound. 2. Gradually the soft corona is replaced with less abundant proteins that have lower dissociation constants, making up the
hard corona. 3. The hard corona may be made up of a complex mixture of proteins, that can vary depending on the region of the body and the physiological state of the human
or animal into which the flakes have been introduced.
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phene forms or preparations, and to identify emerging the consen-
sus views that presently drive research in this area.3. The behaviour of graphene within biological environments
3.1. Graphene and biological fluids
Within cell culture media or biological fluids, it is recognised
that all forms of graphene may potentially interact with compo-
nents of the physiological media. These effects may dramatically
alter the size, shape or surface chemistry of the 2D sheet [49,50].
Two aspects have particular importance: the behaviour of gra-
phene as a colloid, and the formation on the graphene surface of
a protein corona.
GFN suspensions are colloids; therefore, their ability to remain
suspended in solution depends fundamentally on the interaction
between their intrinsic surface chemistry and the chemical
make-up of the suspending media. This problem is critical in phys-
iological media where salts, ions and biomolecules may all interact
with the graphene resulting in flocculation or aggregation of the
previously suspended flakes. For example, while GO is known to
be highly stable in water, when transferred to cell culture media
or buffer it frequently undergoes aggregation [7,15,18,48,51] as
ions and salts in the media screen its negative surface charge
[52] (Fig. 5). Physical factors such as lateral size and flake thickness
contribute to this stability. Smaller flakes have a lower probability
of inter-flake interaction and aggregate less frequently [53].
Solubility may therefore be promoted by extensive washing and
centrifugation, yielding suspensions of thin and laterally small
flakes that contain fewer aggregates [37]. Increasingly however,
additional functionalisation is also employed to stabilise GFNs in
the presence of buffering agents. The most commonly used mate-
rials are PEG [10,49,52,54–57], chitosan [7,42,58,59], dextran
[43,60,61] and serum proteins [62].
The formation of a protein corona is also a substantial compli-
cating factor. When a nanoparticle is introduced to the body a pro-
tein corona forms as serum proteins adsorb to its surface. For GFNflakes this process is dependent on surface features that include
chemistry, geometry and charge [63,64], as well as the proteins
present and their respective concentrations [49,52,63,65]. The pro-
tein corona is considered to be formed of two components – the
hard corona and the soft corona (Fig. 5). The soft corona is made
up of highly abundant but weakly interacting proteins, whereas
the hard corona is made up of less abundant proteins that have a
higher affinity for the nanoparticle surface [64,66]; the soft corona
that forms initially may become replaced over time through com-
petitive binding [64]. The development of a corona may have pos-
itive effects – particle stability may be enhanced since proteins are
predominantly adsorbed via their hydrophobic regions to the basal
plane of the flake, with their charged hydrophilic regions directed
to the exterior, and specific proteins have been used to coat GFNs
before introducing them into physiological media [62,67,68]. How-
ever, adverse interactions also occur affecting biodistribution or
interaction with cells of the immune system [52,64,65,69] or com-
plement system [49,65], particularly in the case of proteins of the
complement system. This latter interaction is one of the most sig-
nificant problems associated with the formation of protein corona,
and will be reviewed in the next section.3.2. Inflammatory and immune responses to graphene
As with other assessments of the graphene–biological interface,
host responses to different GFNs often appear contradictory. How-
ever it is clear that adverse systemic-responses may be evoked by
graphene, and that these responses may be evoked either by GFN
itself, or by any modifications made to it. The complexity of poten-
tial inflammatory interactions is illustrated by effects involving the
protein corona (Section 3.1): Tan et al. [49] showed that in its
native form, GO may bind the complement protein C3 which
may then be cleaved inducing activation of the complement cas-
cade. However following PEGylation of GO, steric repulsion hin-
dered the attachment of larger proteins – modifying the nature
of the protein corona such that the only detectable complement
protein attached was C3/C3a(des-Arg). This process was reported
to impair the normal interaction between C3a and its receptor,
240 C. McCallion et al. / European Journal of Pharmaceutics and Biopharmaceutics 104 (2016) 235–250potentially reducing any adverse complement-response to the gra-
phene flake [53]. However, effects of the protein corona may be
modified by any disease state in the recipient, potentially affecting
outcome: Hajipour et al. [66] demonstrated that GO flakes exposed
to serum proteins from patients experiencing a range of different
disease states, induced different toxicities when introduced to cells
in vitro.
Beyond the interaction with the protein corona, GO and pristine
graphene are both recognised to be ingested by macrophages,
inducing cell activation and secretion of pro-inflammatory cytoki-
nes [70–73]. These effects depend significantly on the geometry of
the graphene flakes used. It has repeatedly been shown that the
inflammatory response to graphene preparations becomes more
pronounced as lateral flake-dimensions increase both in vitro and
in vivo. In a study involving GO flakes of two distinct dimensions
(approximately 350 nm and 2 lm), it was found that the larger
flakes provoked a significantly increased secretion of inflammatory
cytokines by macrophage cell lines in vitro [74]. Similarly in vivo,
large flake size was shown to induce a more significant influx of
lymphocytes and macrophages into adipose tissues following sub-
cutaneous injection. TEM study revealed wrinkles in the structure
of larger flakes following phagocytosis, and it was postulated that
these forms are more chemically reactive since the bonds between
carbon atoms in these regions become bent, causing the electron
clouds of the carbon atoms to fall outside of the plane of the flake
[80]. Such effects may differ however according to recipient species
and the dose interval employed. The secretion of pro-inflammatory
cytokines may be less marked in human cells [73] than in murine
macrophages [70–72]; in a mouse model, multiple doses of small
GO flakes resulted in the accumulation of inflammatory cellsTable 1
A summary of important results on immunogenicity of different graphene forms.
Refs. Functionalisation Geometry Concentration
Immunotoxicity
[70] Pristine graphene 150–200 nm
Few layer
20 mg/kg; (murin
[72] Pristine graphene + pluronic F108
(1%)
10–100 s nm
Few layer
20 lg/mL; primar
& RAW264.7
[49] GO 63 lm
1–2 layers
0.4 mg/mL; prima
GO-PEG (biotin) 10–50 nm
1–2 layers
0.4 mg/mL; prima
[71] GO 63 lm
Few layer
5 or 100 lg/mL; R
10–100 s nm
Few layer
5 or 100 lg/mL; R
[73] GO 1.32 lm 1–100 lg/mL; pri
macrophages & p
macrophages
270 nm
130 nm
[74] GO 2 lm 2 lg/mL; primary
subcutaneous inje
350 nm
[76] GO 100 nm–lm 1–25 lg/mL; bone
dendritic cells
[83] GO nm to lm range
Few layer
25–100 lg/mL; pr
cells & primary T-
GO + polyvinylpyrrolidone (PVP) 100 s nm
Few layer; 2.5 nm
thickwithin hepatic tissues that were not observed with other flake size
or dosing strategies [75].
The effects of graphene extend also to the adaptive immune
system, where graphene has been shown to suppress interactions
between dendritic cells and T lymphocytes [76]. Using an ovalbu-
min antigen (OVA) system, bone-marrow dendritic cells were used
to stimulate T-lymphocytes in the presence of either GO or fullere-
nes (unfunctionalised or TRIS-functionalised). Low doses of fullere-
nes (6.25 lg/mL) increased IL-2 secretion by T-cells, whereas GO
significantly reduced the T-cell activation at all concentrations.
The authors used molecular modelling to demonstrate that GO
strongly interacts with the LMP7 molecule (a critical immunopro-
teasome subunit) through charged residues; the corresponding
interaction with the fullerenes was far weaker, being solely depen-
dent on hydrophobic and p–p interactions, and was restricted by
the smaller lateral dimensions of the fullerene [76]. Together, these
studies highlight the importance of graphene preparation, cell
model and experimental approach when evaluating graphene in
a biological context.
Functionalisation of GFN flakes may be used to modify cell-
induced inflammatory or immunological effects. Zhi et al. [77]
coated GO flakes with polyvinylpyrrolidone (PVP), comparing the
effects of native GO and PVP-GO in vitro using macrophages and
immature dendritic cells (DCs) from healthy human volunteers.
Both GO and PVP-GO were found to activate immature DCs,
inducing dose-dependent maturation, up-regulation of activation
markers, and secretion of inflammatory cytokines, causing
dose-dependent release of pro-apoptotic cytokines by the
T-lymphocytes. In each case however, native GO produced a more
significant response than PVP-GO [77]. More recently, Paul et al.Response
e model) IL2, IL4, IL13, TGFB1 & TNF-a overexpression
y murine macrophages IL-1a, IL-6, IL-10, TNF-a and GM-CSF, MCP-1, MIP-1a,
MIP-1b & RANTES upregulation
ry human serum Non-specific adsorption of serum proteins?
complement cascade
ry human serum Specific adsorption: C3a(des-Arg), PF4, vitronectin,
clusterin, thrombin & HRG
AW 264.7 TLR signalling cascades, IL-2, IL10, IFN-c, TNF-a
secretion
AW264.7
mary human
rimary murine
Murine cells: 25 lg/mL – significant IL1b secretion
Human cells: 100 lg/mL – CD86 expression
Murine cells: 25 lg/mL – significant CD86
expression; 50–100 lg/mL – significant TNFa
Human cells: 100 lg/mL – CD86 expression
Murine cells: 25 lg/mL – significant CD86
expression; 25–100 lg/mL – significant TNFa
expression; 25–50 lg/mL – significant IL1b secretion
murine macrophages;
ction (murine model)
TNF-a, TNF-c, MCP and IL-6: significant secretion
increase
Significant migration of inflammation cells after 21 d
Inflammatory cytokines: no significant increase
Some migration of inflammation cells after 21 d
marrow-derived Reduction in dendritic cells’ stimulation of T-cells
after OVA exposure
imary human dendritic
lymphocytes
100 lg/mL: significant TNF-a and IL-1b increase
25–100 lg/mL: significant IL-6 increase
50–100/mL: significant IL-6 increase
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the GO flakes were additionally functionalised with polyethylen-
imine (PEI), for the delivery of vascular endothelial growth factor
(VEGF) post-myocardial infarction. The nanocomposite was tested
in vivo, in an immunocompetentmousemodel, and itwas found that
the composite produced negligible immunogenicity. It was sug-
gested that the embedding of the GO flakes in a hydrogel caused a
controlled release, which is akin to administering multiple low
doses of the GO nanocomposite over time; the results demonstrate
the potential of themethod tominimiseunwanted side effectswhile
avoiding repeated administration. Sasidharan et al. [79] also
demonstrated that functional modifications significantly modify
immune responses observed in vivo. Employing few-layer pristine
graphene flakes (p-FLGs) prepared using the arc discharge method,
then used directly or functionalised with either carboxyl groups
(FLG-COOH) and PEGylated (PEG-FLGs), the three preparations of
flakes were administered to Swiss albino mice, and immunological
and inflammatory cytokinesweremonitored 1 and 8 days following
administration. All preparations led to acute altered expression of
genes associated with inflammation and immune response. On
day 1 almost all the gene expression levels were up-regulated –
most significantly by p-FLGs – whereas on day 8, many had been
down-regulated, and in those treated with FLG-PEG most gene-
expression levels resembled the control at 8 days post-treatment.
Histological samples following p-FLG and FLG-COOH exposure also
showed evidence of inflammation, even after 90 days, whereas PEG-
FLG did not.
A summary of immunogenic responses to GFNs reported in the
literature is presented in Table 1.
3.3. Interaction of graphene with the blood components
Compatibility with blood components is required for effective
drug-delivery in many contexts. A range of studies have therefore
addressed this aspect.
GFNs can interact strongly with cell membranes, and may
induce membrane-damage through the formation of reactive oxy-
gen species (ROS). Red blood cells lack significant repair capability
and have reduced capability to respond to oxidative stress. The
premature breakdown of red cells (haemolysis) is therefore a sen-
sitive indicator of damage induced by graphene [61,80–82]. Sasdi-
haran et al. [83] compared pristine graphene with GO; the pristine
graphene was prepared using direct-current arc discharge evapo-
ration of graphite (forming flakes with lateral dimensions in the
hundreds of nanometres and sub-nanometre thicknesses), while
to prepare the GO the pristine-graphene flakes were refluxed in
nitric acid. Both GO and pristine graphene were found to aggregate
in cell culture media, and the aggregates clustered around the ery-
throcytes on TEM images. However, neither preparation invoked
significant haemolysis in the tested concentration range of 0–
75 lg/mL. By contrast, Liao et al. [8] compared the haemocompat-
ibility of GO, rGO and chitosan-coated GO: the GO was produced
using a modified Hummers’ method and rGOwas produced by sub-
jecting the GO to hydrothermal treatment at low pH (both being
significantly different methods to those used by Sasidharan et al.
[84]). Each preparation was observed to aggregate; however, in
this case all samples invoked haemolysis, even at concentrations
less than 50 lg/mL. This latter result was confirmed by other
groups using a modified Hummers’ method to prepare their sus-
pensions [85]. When optical microscopy was used to evaluate
graphene-induced morphological changes in erythrocytes exposed
to a range of flake thicknesses and lateral sizes (prepared by vary-
ing sonication time and intensity with lateral sizes ranging from
the nanometre range up to approximately 10 lm), it was shown
that the most exfoliated GO flakes induced the most extensive
membrane damage, while modified preparations (rGO andchitosan-coated GO) caused the least damage. The authors con-
cluded that these results were due to the aggregation of both the
modified preparations, and because chitosan prevented electro-
static interaction between the GO functional groups and the ery-
throcyte membranes. In addition to the methods used to prepare
the different GFNs between reports, other methodological
approaches may not have been equivalent in the different experi-
mental systems. Standard methods suspend the particles in phos-
phate buffered saline (PBS) (as stated explicitly by Sasidharan et al.
[83]), however other publications were less clear about the meth-
ods used, and potentially employed dispersion media containing
adsorbents or ionic species that could affect the surface chemistry
of the flakes, changing their interactions with red blood cells.
The activation of human platelets in vitro is a significant adverse
effect of many substances introduced to the body. In early experi-
ments GO prepared using a modified Hummers’ method was
reported to induce thrombosis following injection into mice, and
it was concluded that the platelet aggregation was induced by their
interaction with the negatively charged surface of the GO flakes
[85] – similar to the effects of the negatively-charged surface of
collagen in vivo [86]. rGO flakes which had fewer charged groups
on their surface were shown to be less thrombogenic [85]. Testing
this hypothesis further, the authors employed positively-charged
flakes using rGO subsequently functionalised with amine groups
(producing amine modified graphene (G-NH2))[80]. Whereas GO
was shown to induce platelet activation and aggregation at doses
of only 10 lg/mL, G-NH2 showed no significant effect at the same
doses. The difference was further confirmed in vivo: doses of
250 lg/kg of GO induced thrombosis to a similar extent to those
treated with the platelet activating agent collagen (200 lg/mL),
while those treated with the same concentration of G-NH2 showed
no increased thrombotic tendency [80]. Other reports have demon-
strated that alternative functionalisation could modify this effect:
Chowdhury et al. [61] measured platelet factor 4 levels in whole
blood taken from two donors and found that GO-Dextran at doses
of 1–10 mg/mL caused no platelet activation. Similarly Shen et al.
found that GO-Fe3O4 prepared either as nanoparticles or sheets
did not invoke a thrombotic response [87].
3.4. Bioaccumulation of graphene
The kinetics of biodistribution, including excretion or bioaccu-
mulation, of nanoparticles are significantly linked to both particle
size and geometry: research using non-graphene nanoparticles
has shown that particles with diameters less than 30 nm are
rapidly excreted by the kidneys, while large particles (above
500 nm) are phagocytosed and cleared through the reticulo-
endothelial system (RES); particles of intermediate size may accu-
mulate in the bone marrow, heart, stomach, kidneys, liver and
spleen [52]. Similar processes appear to be reflected in the beha-
viour of graphene. Moore et al. found that large flakes of PEG- or
polymer-functionalised hydroxylated-graphene were cleared more
rapidly than similarly functionalised small CNTs, and that they
accumulated in the organs of the RES rather than the brain tissue
to which they had been targeted [23]. Flake geometry was also
found to be crucial to accumulation. Shen et al. [87], using a mur-
ine model, compared GO-FE3O4 wrapped nanoparticles with gra-
phene in sheet-like structure where FE3O4 was attached to the
surface (nanosheets). Iron levels were used to track the distribution
and excretion of each graphene form. For the nanoparticle form of
GO-FE3O4 the iron levels returned to baseline after 14 days sug-
gesting effective elimination; in contrast, iron levels in animals
exposed to nanosheets remained elevated. This difference was
reflected in the observed residence behaviour: both forms initially
were concentrated in the lung and spleen before a steady increase
in the liver; however, there was a sharp peak in kidney residence at
Table 2
Summary of a selection of results from the literature in which GFNs were found to induce ROS generation, including the concentration at which ROS generation became
significant, compared to a control.
References Significant concentration (lg/mL) Functionalisation Geometry Cell type Time (h)
Reactive oxygenated species generation
[93] 10–100 Pristine 3–5 layer, 10–100 nm PC12 24
[84] 50–100 Pristine Single layer
>2.5 lm
Vero 24
– Carboxylated
[9] 5–20 Pristine in pluronic F108 Few layer
0.5–1 lm
RAW264.7 24–48
[111] 10–100 rGO + BSA 11 nm hMSCs 1
10–100 91 nm
10–100 418 nm
100 3.8 lm
[83] 75 Pristine 1–2 layer
100 s of nm
RAW264.7 24
– Carboxylated
[99] 10 GO 0.4–0.8 lm HUVECs 24
0.2–0.8 lm
rGO 0.4–0.8 lm
0.2–0.8 lm
[96] 100 rGO 50–200 nm  10 lm
Monolayer
hMSCs 1
10 5
1 96
100 Low aspect ratio. No other details 1
10 24–96
[98] 10 GO Monolayer
>1 lm
Murine spermatazoa 2
10 rGO – N2H4
10 rGO – HT
– rGO – GTP Monolayer (with adsorbed GTPs)
Table 3
Summary of a selection of results from the literature where membrane disruption by GFNs was investigated, including the concentration of GFNs at which membrane disruption
became significant, compared to a control.
References Significant concentration (lg/mL) Functionalisation Geometry Cell type Time (h)
Membrane disruption
[93] 100 None – pristine 3–5 layer, 10–100 nm PC12 24
[84] None Pristine Single layer
>2.5 lm
Vero 24
Carboxylated
[83] – Pristine 1–2 layer
100 s of nm
RAW264.7 24
Carboxylated
[99] 5–10 GO 0.4–0.8 lm HUVECs 24
1–10 48
1–10 0.2–0.8 lm 24
1–10 48
10 rGO 0.4–0.8 lm 24
10 48
10 0.2–0.8 lm 24
1–10 48
[96] 100 rGO 50–200 nm  10 lm
Monolayer
hMSCs 1
10 5
1 96
100 Low aspect ratio. No other details 24–96
[103] – GO 700  200 nm
No thickness stated
A549
MCF7
–
– 300 nm
No thickness stated
–
– 200 nm
No thickness stated
–
100 100 nm
No thickness stated
72
[101] 200–400 GO 125–220 nm  500–2500 nm
Few layer
HeLa 72
– SKBR3 72
– mcf7 72
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ing excretion), while nanosheets had steady and low residence in
the kidney that increased sharply after 14 days.Accumulation and aggregation of nanoparticles that cannot be
degraded may induce the formation of granulomas through frus-
trated phagocytosis by macrophages – a process that is well recog-
Table 4
Summary of results from the literature in which the genotoxicity of GFNs was examined, including the concentration at which genotoxicity became significant, compared to a
control.
References Significant concentration (lg/mL) Functionalisation Geometry Cell type Time (h)
Genotoxicity
[100] 0.1–100 rGO + BSA 11 nm hMSCs 1
1–100 91 nm
100 418 nm
100 3.8 lm
[101] 1 rGO 50–200 nm  10 lm
Monolayer
hMSCs 1
0.1 5
0.01 96
[103] 100 GO Monolayer
>1 lm
Murine spermatazoa 2
100 rGO – N2H4
100 rGO – HT
– rGO – GTP Monolayer (with adsorbed GTPs)
[61] 100 GO 400–500 nm
Few layer
7702-3d, MRC-5-3d, U937-3d 24
– GO-PEG 30 nm
Few layer (1–2 nm)
–
– rGO-PEG 70 nm
Few layer (4–5 nm)
200 GO-BSA 50 nm
Few layer (10 nm)
48
– rGO-BSA 70 nm
Few layer (15 nm)
–
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nificant interest in the potential for degradation of graphene flakes
and related carbon nanomaterials. Kotchey et al. demonstrated
that horse radish peroxidase (HRP) was able to further oxidise
GO, causing holes to form in its basal surface [89], while Kagan
et al. reported that neutrophil myeloperoxidase could degrade
shorter CNTs [90]. Additional evidence has been presented using
in vivo models: Girish et al. [70] used Raman spectroscopy to show
that carboxylated graphene introduced to mice by tail-vein injec-
tion aggregated and accumulated in the lung, liver, kidney and
spleen, but was partially degraded over time, such that after
3 months the intensity of the graphene signal in the lungs was
reduced – particularly around the edge regions – and within the
spleen the characteristic Raman signal associated with amorphous
carbon was observed at the edges of aggregates – indicating signif-
icant degradation. The same authors confirmed their findings using
murine macrophages in vitro, confirming graphene uptake within
24 h and significant degradation of the endocytosed graphene
flakes by the seventh day, with approximately 50% of the total area
of the flakes showing some degradation.
Bioaccumulation may also be significantly affected by function-
alisation of GFNs; for example, PEG is often used to increase the
biocompatibility and circulation time of GO, but has low
biodegradability and may therefore potentially increase the bioac-
cumulation of the graphene. Li et al. [55] compared non-
functionalised GO with PEGylated GO (PEG-GO) using human
macrophage, lung fibroblast and liver cell lines in vitro. The group
confirmed that PEG-GO caused less direct toxicity, but also that it
underwent less degradation. To address this, the group used disul-
phide bonds to covalently link the PEG to the GO, which may be
cleaved by intracellular enzymes potentially allowing the GO to
be degraded following its interaction with the target cell.4. Cellular toxicity of graphene
4.1. Importance of both chemical and physical form
Cells may die through either of two main routes: programmed
cell death (apoptosis) or spontaneous cell death (necrosis). For
nanomaterials both mechanisms are relevant and relate to bothstructural and chemical properties. Apoptosis may be triggered
by reactive oxygen species (ROS) (see Table 2) or other toxic ele-
ments associated with the particles, while necrosis may be induced
by direct damage to the plasma membrane resulting from specific
physical properties of the particles (see Table 3). In addition, if the
nanoparticles are able to enter the nucleus, there is concern that
they could interact directly with the cell’s DNA, resulting in geno-
toxicity (see Table 4). Study of the cellular toxicity of GFNs has
therefore focused on each of these processes, and has considered
both the physical characteristics of the material (such as lateral
size, layer number, shape and hydrophobicity) and important
chemical properties including functionalisation and molecules
associated with the preparation or delivery media.
The relative importance of these properties is not equally repre-
sented between the different graphene forms or target cell types or
tissues. The importance of both the chemical and physical form of
the flakes is notably shown in those studies where similar cell sys-
tems or models produce apparently contradictory results, and is
particularly apparent in vivo where the complexity of the system
and the range of cells exposed require a more holistic view of the
toxicological profile of different graphene preparations. Therefore,
while the following sections are split in terms of GFN surface
chemistry, the significance of graphene flake geometry – particu-
larly the importance of both lateral dimensions and layer number
– cannot be understated in determining toxicity. In addition, since
particle size and geometry vary substantially according to prepara-
tion methods, this introduces additional complexity to the assess-
ment of graphene toxicity. For these reasons, the geometry of the
flakes is highlighted within the sections, and the geometry and
thickness of graphene preparations for the quoted publications
are highlighted in Tables 2–4, which may be used for reference
between studies.
4.2. Pristine graphene
Pristine graphene form has low intrinsic solubility and therefore
requires additional solubilisation steps to support its use within
biological systems, and the additional compounds required to
achieve this may affect its toxicity. Both PEG and the block co-
polymer surfactant Pluronic F108 are widely used in biomedicine
to improve the biocompatibility of nano and microparticles, and
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logical profile of CNTs [91]. For pristine graphene it is recognised
that Pluronic F108 interacts through the hydrophobic regions of
the flake while the hydrophilic PEG tail-regions of the molecule
extend into the media [9]. Solubility is promoted by this, but the
surface chemistry of the graphene flakes is significantly altered.
The pristine-graphene/Pluronic F108 compound was found to
induce the apoptotic death of murine macrophages in a time and
dose dependent manner that was attributed to depletion of the
mitochondrial membrane potential significantly increasing ROS
within the cell and triggering apoptotic pathways [9]. This effect
appears to derive from the graphene component rather than of
the surfactant however, since in other studies using pristine gra-
phene alone similar effects were observed, with reduced metabolic
activity [83,92,93] caused by an increase in ROS, often leading to
apoptosis and in some cases cytoskeletal dysfunction [83]. In con-
trast, the lactate dehydrogenase (LDH) leakage associated with cell
necrosis was observed to be minimal [83,92] (although caution
should be taken with this mode of assessing toxicity, as GFNs are
known to interact with the assay by binding to LDH, and can there-
fore give false negative results).
Studies in vivo have supported the concept of significant
toxicity for pristine graphene with organ-specific effects being
identified. Sawosz et al. [94] investigated the effects of pristine gra-
phene on chicken embryos. The graphene was introduced to the
ovalbumin before fertilisation, and hence was present before the
blood–brain barrier formed. The authors found that although there
was no significant reduction in the weights of the liver, brain, heart
or spleens of the embryos after 19 days of incubation, the survival
rate significantly decreased for all concentrations (50–10000 lg/L).
TEM images showed that tissue and cells in the cerebrum were
found to have abnormal ultrastructure, believed to derive from
strong interactions between the hydrophobic basal plane of the
graphene and the lipid membranes within the cerebral milieu.
Evidence of additional cellular disruption was demonstrated by
the reduction of PCNA expression, which is associated with DNA
synthesis and repair [94]. Similarly, Sasidharan et al. [79] demon-
strated cellular damage from pristine graphene using a few-layer
preparation (p-FLGs) prepared by the arc discharge method, to pro-
duce flakes of lateral dimensions 200–400 nm, to which they
exposed via tail-vein injection, Swiss albino mice over a period of
3 months. Through serum biochemistry analysis it was found that
alkaline phosphatase and blood urea nitrogen levels increased over
the 90 days to levels significantly higher than the control, indicat-
ing hepatic injury.
4.3. Reduced graphene oxide
The reduction of GO to form rGO removes the majority of the
oxygenated functional groups. However, unlike pristine graphene,
residual oxygenated functional groups remain on rGO conferring
distinctive properties to the material. Like pristine graphene, the
hydrophobicity of the rGO allows it to interact directly with cells
causing direct physical damage; however, the extent to which this
occurs is dependent also on other properties of the flakes. Akhavan
et al. showed that reduced dimensions in one or both of the lateral
planes of rGO had substantial impact on the cytotoxicity the sheets
[95,96]. Different preparations of rGO were all shown to disrupt
cell membranes and induce ROS generation within primary mes-
enchymal stem-cells; however, toxicity was substantially greater
when rGO was in nanoplatelet or nanoribbon formwhen compared
with rGO that had large lateral dimensions. Other studies have
confirmed this effect of particle dimension [97].
In addition, the surface chemistry of rGO may differ signifi-
cantly depending on how it is prepared. Hashemi et al. [98] tested
the viability of spermatozoa exposed to rGO prepared using one ofthree different methods: hydrazine (HZrGO), high temperature
(HTrGO) or green tea polyphenol (GTrGO) reduction. Each prepara-
tion induced increased ROS levels and nitrous oxide (NO) produc-
tion, causing DNA fragmentation and low ATP levels with reduced
motion of the spermatozoa. However, this effect was more marked
for HTrGO and HzrGO forms than for GTrGO. The authors sug-
gested that residual green tea polyphenols adsorbed to the flake
surfaces of GTrGO provided partial protection. An effect of the
preparation method on the physical characteristics of the rGO
was also noted: the most hydrophobic particles (HzrGO) were also
the thinnest and sharpest, and had highest toxicity.
A further element in rGO toxicity may relate to the aggregation
or sedimentation of the molecule and the nature of the target cell
type. Liao et al. [8] compared the toxicity of rGO and GO using
human erythrocytes and skin fibroblasts. They showed that while
rGO induced less haemolysis, it was more toxic to fibroblasts. This
was attributed to increased sedimentation and aggregation of
rGO, causing much of it to settle on top of the adherent fibroblast
layer, which the authors suggest may have restricted the cells’
access to nutrients.
4.4. Graphene oxide
The toxicity associated with oxygenated functional groups pre-
sent on GO flakes introduces potential toxicity. However, the
extent of the toxicity caused by this oxygenation is unclear, with
separate studies reporting different outcomes. Das et al. [99] pre-
pared GO using a modified Hummers’ method, flakes were exposed
to hydrazine hydrate for different lengths of time, generating flakes
that had different densities of oxygenated functional groups, with
the least stable flakes being somewhat stabilised using ammonium
hydroxide. Using a Human Umbilical Vein Endothelial Cell
(HUVEC) model, the group demonstrated that a higher density of
oxygenated functional groups was associated with increased levels
of ROS and associated DNA-damage within cells (quantified using
the oxidant-sensitive dye H2-dichlorofluorescein, together with
the assessment of heme oxygenase-1 and thioredoxin-reductase).
The increase in ROS was associated with altered cell attachment,
morphology, cell survival and proliferation [99]. However, in an
alternative approach by Sasidharan et al. [84], GO was first reduced
using thermal exfoliation, following which, the flakes were car-
boxylated to varying extents. The flakes were then tested using
cultures of Vero (monkey kidney) cells, and the carboxylated flakes
were shown to disperse well in media and to be taken up by the
cells, with metabolic activity (assessed using Alamar Blue), mem-
brane integrity (LDH release) and survival all unaffected.
As highlighted for other graphenepreparations, shape and aspect
ratio contribute significantly to the toxicity of GO [96,100,101].
Kimh Chng et al. [100] compared two GO samples of differing
geometries, both prepared using the same modified Hummers’
method; low aspect ratio flakes were derived from oxidised and
exfoliated graphene nanofibres with dimensions 100  100 nm
(nGO flakes), while high aspect ratio graphene oxide nanoribbons
(GONRs) of dimensions 310  5000 nm prepared from ‘‘unzipped”
multiwalled carbon nanotubes (MWCNTs). Using cytotoxicity
assays involving A549 (lung epithelial) cells, dose-dependent toxic-
ity was observed for both preparations; however, toxicity was con-
sistently greater for GONRs compared with nGO flakes, with an
almost fourfold difference in the concentration required for a signif-
icant toxic effect (detected byMTT andWST-8 assays). In a separate
study, GONRs were submitted to sonication using different intensi-
ties or lengths of time. Longer sonication is associated with smaller
flake size [8], decreased aspect ratios [100], and an increased
number of structural defects [102]. Using twohuman carcinoma cell
lines and Oryzias Latipes embryos, it was found these features were
associated with greater toxicity to the cells [103].
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ments of the various studies. The effects of aspect ratio are intrin-
sically linked to different overall lateral sizes of the GO flakes, and
the methods required for sample preparation carry a significant
effect. The unzipping method of producing GNRs is reported to
result in a high proportion of carbonyl groups situated along the
GNR edge [100] – for nanoribbons this may contribute to the high
toxicity observed [101]. Furthermore, residual contaminants asso-
ciated with GO preparation may include metals and mellitic acids
adsorbed to the flakes; the removal of these contaminants may
require additional steps, such as hydrochloric acid treatment
[104] and multiple washing steps [37]. In addition, without multi-
ple centrifugation and washing steps, larger and thicker flakes, and
unreacted graphite may remain in suspension; without carrying
out such steps, it becomes difficult to pinpoint the causes for any
observed toxicity.
In vivo studies have enabled the assessment of chronic effects of
GO exposure, and of dosing strategy. A high dose of GO (500 lg/
mL) administered to maternal mice during their lactation period
caused developmental delay to offspring and morphological abnor-
malities of the intestinal Villi of the young mice [105]. Using a
mouse model, Liu et al. [75] compared two different GO flake-
sizes (greater or less than 1 lm) and a range of doses delivered
either as single injections (0.3, 2.1 or 10 mg/kg) or as seven succes-
sive doses (0.3 mg/kg per dose, up to a total exposure of 2.1 mg/
kg). For both flake sizes, the lower single doses (0.3–2.1 mg/kg)
had low mortality rates and organ size was not affected; in con-
trast, the highest single dose (10 mg/kg) induced a very high mor-
tality rate. Mice from the multiple-dose group also experienced
high toxicity: three died before the end of the investigation, and
the mice showed increased lung size with GO-filled macrophage
nodules, in addition to significant swelling in the renal glomeruli
with biochemical evidence of renal impairment. The mechanism
of toxicity did not appear to be the same as was seen in vitro, since
apoptosis in affected organs was not significantly different from
that in the control group, and oxidative stress markers in the liver,
spleen and lungs were found to be at normal levels, perhaps
because of a protective effect of the serum proteins adsorbed to
the GO flakes [75]. The authors concluded that multiple low doses
of GO flakes may allow an acceptable toxicological profile.
4.5. Further-functionalised GFNs
In general, while the nature or extent of toxicity for pristine
graphene, rGO or GO may vary, most native GFNs have been found
to produce significant cytotoxic responses. This has prompted the
use of functionalisation to reduce this effect. In biomedicine
significant attention has focused on polyethylene glycol (PEG)
[48,51,55,106,107]. This molecule may be attached covalently,
with bonds that are cleavable [55] or non-cleavable, or through
hydrophobic attachment as block co-polymers [48,107]. PEG is
recognised to increase the circulation time and biocompatibility
of graphene, and is widely used to functionalise micro and
nanoparticles for therapeutics delivery. Attachment of dextran
may also provide similar benefits [60,61,108]. The advantages of
functionalisation using PEG were shown by Moore et al. [23],
who used a hydroxyl-functionalised graphene that was complexed
with PEG and poly(lactide) (GrLP). The toxicity of the complex was
compared with hydroxylated graphene (h-Gr) in vitro using U138
human glioblastoma cells. The authors demonstrated dose-
dependent toxicity for uncoated hydroxylated graphene commenc-
ing at concentrations of 50 lg/mL, whereas dose-dependent toxic-
ity was not observed for GrLP at concentrations up to 250 lg/mL.
Kanakia et al. [108] used GO-dextran composites to perform a
safety pharmacology assessment; the superior stability of the com-
posite compared to unfunctionalised GO allowed them to test themaximum tolerable dose (MTD) without the restrictions imposed
by the limited stability of native GO. The authors found that if
the suspension was given as a rapid bolus injection, significant
mortality was observed at concentrations P125 mg/kg, whereas
similar mortality rates were only observed at concentrations
P250 mg/kg when the dosage was given at a slower injection rate.
When dosages exceeded 250 mg/kg, histological sections of the
heart, liver, lung and kidney revealed adverse pathological
responses, predominantly in the form of congested blood vessels.
In contrast, lower concentrations had no significant impact on
the cardiovascular system or on the blood composition. Interest-
ingly, as the concentrations of GO-dextran increased, proportion-
ally more of the suspension was rapidly excreted, whereas low
concentration GO was found to accumulate in the organs both
immediately after injection, and after 30 days. Similar results were
reported by Yang et al. [109], who tracked the distribution of 125I-
PEG-GO in mice (either 4 or 20 mg/kg). Reflecting previous reports,
the majority of the flakes were found to accumulate in the organs
of the RES, before being excreted. Although GO-PEG aggregates
were observed in histology sections of the liver taken at 3 days,
most were cleared by 20 days with no injury to the liver, kidney
or spleen observed up to 90 days. Using a novel radiolabelled
preparation of chemically-functionalised graphene, Jasim et al.
[110] employed whole body single photon emission computed
tomography (SPECT/CT) imaging combined with Ramen spec-
troscopy. The authors demonstrated that following injection into
blood the graphene sheets underwent renal clearance, with
retained graphene being present initially in liver before later accu-
mulation in spleen (24 h). The authors noted however that the
results obtained in their own study differed from other reported
studies of the fate of graphene flakes administered in vivo. They
specifically identified differences in the nature of the graphene
flakes used in the different studies. The authors of the study make
the important point that graphene-flake geometry plays a major
role in determining the fate of administered functionalised gra-
phene, identifying an importance of particle dimension as a deter-
minant of uptake by both cell type and tissue [110].
It has been shown also that the toxicity of functional molecules
may be also be modified through their association with graphene
flakes. This may be illustrated by the compound PEI, a cationic
polymer useful in therapeutics delivery in vitro. The molecule is
able to condense nucleic acids and to escape the endosomal vesi-
cles using the proton sponge effect. The compound has not reached
the clinic as it has significant cytotoxicity. However, when in com-
plex with GO the toxicity is reduced, possibly due to the reduction
in free branches of the PEI polymer [18].
Summaries of a range of toxicology results for various GFNs are
presented in Tables 2–4.5. Graphene: a therapeutic platform
5.1. Cargo attachment
The way in which a cargo is loaded onto or into therapeutics
delivery vehicles influences how well the cargo is protected from
degradation, how it may be released at its site of action, and even
the size and shape of the vehicle itself. The flexibility of the gra-
phene platform has allowed exploitation of each of these aspects.
Initial work with GFNs used drugs that interact directly with
graphene sheets, often through their aromatic or hydrophobic
regions [112]. For instance, SN38 binds to graphene by hydropho-
bic interactions and p–p stacking [51], while for doxorubicin
(DOX) binding may additionally employ hydrogen bonding to oxy-
genated functional groups, allowing pH-controlled loading and
release [44]; in both cases, drug effectiveness was increased com-
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including genetic materials have been complexed to graphene to
protect them from degradation. For single stranded nucleic acids
this has employed adsorption through interaction of the nucle-
obases with the polyaromatic basal plane of graphene or other car-
bon nanomaterials [1,113–115]. The effectiveness of this approach
was demonstrated by Lu et al. who adsorbed a molecular beacon
(MB) to GO via p–p interactions. The adsorbed genetic material
was shown to be protected from degradation (by the enzyme
DNAse I), and to be successfully released within a HeLa cell model
where the hairpin looped oligonucleotide was shown to fluoresce
when in contact with its complementary sequence [5]. To deliver
double-stranded nucleic acids further functionalisation is required,
and compounds that are already used in gene therapy are often
employed. Zhang et al. [16] used PEI to functionalise GO, permit-
ting the condensation of double stranded Bcl-2 targeted siRNA
(short interrupting RNA) to the functionalised graphene through
electrostatic interactions. Exploiting the high surface area of gra-
phene, the group was able additionally to load DOX onto the flakes,
although they reported that sequential rather than co-delivery of
DOX and siRNA was more effective [16]. Since that report, other
groups have also used PEI-functionalised GO for gene delivery
[15,17,18,116]; this and other cationic polymers are particularly
attractive as they are able to facilitate the condensation and com-
plexation of negatively charged nucleic acids, and may promote
interactions with the negatively charged cell membranes.
The complexation of graphene and polymers or other functional
species can significantly change the size and geometry of a gra-
phene flake, as found by Kim et al. [47], who showed that after
complexation with PEI and PEG, their rGO flakes became signifi-
cantly smaller and more globular. The capability to intentionally
modify vehicle-shape by tailored drug-binding was demonstrated
by Yang et al. [112]. Low molecular weight PDMAEMA (Poly(2-di
methylamino-ethylmethacrylate) was attached to GO flakes using
disulphide bonds (denoted using SS). The favourable interactions
between pDNA and the short PDMAEMA chains was then exploited
to induce the formation of a complex nanoparticle, made up of
multiple GO-SS-PDMAEMA sheets with pDNA macromolecules
sandwiched between them. The starting sheets were approxi-
mately 10 nm in thickness with lateral dimensions around
500 nm before complexation with pDNA, but following pDNA com-
plexation the resultant nanoparticle was globular with an average
diameter of 86 nm. The particle therefore contained multiple plas-
mids and had a size that favoured its endocytosis, while cleavage of
its disulphide bonds permitted fragmentation within the cell.
5.2. Cell targeting
Following attachment to graphene, the cargo must be trans-
ported to its target cell or the tissue where the compound should
be preferentially taken up and released. Again the flexibility of
the graphene platform has been used to support a range of
approaches.
Passive targeting mechanisms are attractive since they do not
require extensive functionalisation, and these have been exploited
using a graphene platform. The enhanced permeability and reten-
tion (EPR) effect is a well-used phenomenon in which the over-
vascularisation, leaky vasculature and reduced lymphatic drainage
in cancerous tumours means that nanoparticles, including GFNs,
delivered through the circulation tend to preferentially accumulate
in the tumour. This has been effectively demonstrated by a number
of groups [23,117,118], many of whom loaded their GFNs with
labels to allow imaging in vivo – for example magnetic nanoparti-
cles for magnetic resonance imaging (MRI) [118] or fluorescent
moieties for near infrared fluorescence (NIRF) imaging [119]. In
addition to illustrating the biodistribution of the flakes, such stud-ies show the capacity of using GFNs as theranostic probes. The EPR
effect may be made more specific through the use of additional
physical methods. For example, the high infra-red absorption
capacity of graphene or GO allows photothermal effects to be
exploited for localised cell killing through hyperthermia, where
the infrared light is applied only to the area being targeted [120–
124]; localised heating through photothermal means has also been
shown to increase cell permeability, additionally increasing the
transfection efficiency of the graphene complexes in the region
where the infrared light is applied [125]. Similarly, GFN-magnetic
nanoparticle composites have also been prepared so that graphene
particles can be specifically targeted using localised magnetic
fields [120,126].
In a particularly interesting example, Feng et al. [121] used the
difference in pH in the tumour microenvironment to change their
GFN’s propensity for uptake; the flakes were loaded with DOX and
conjugated with PEG and a pH responsive polymer. In neutral or
basic environments, the flakes were negatively charged, but when
introduced to an acidic environment their charge becomes positive
– making interaction with the negative cell membrane and subse-
quent endocytosis far more likely. The authors used fluorescence
imaging and flow cytometry, in addition to the increase in cell
death following DOX-loading, to illustrate a significant improve-
ment in cell uptake and drug delivery in acidic conditions com-
pared to neutral conditions. Finally, photothermal ablation was
used to further enhance cancer cell killing, showing additional
improvements on rates of cell death.
A more specific interaction with particular cells or tissue types
may be achieved through the linkage of ligands that are recognised
by cell-surface receptors. This method allows the targeting of
graphene/drug complexes to particular cell types or tissues, and
also may facilitate cell uptake and promote specific modes of intra-
cellular trafficking. This active-targeting approach has been exem-
plified by studies that exploit the interaction between the folate
molecule and its specific receptor. The folate receptor is widely
expressed, but has overexpression on the surfaces of particular can-
cer cells [42,124,127]. Folate itself has no intrinsic toxicity and is
thought to be taken up through receptor mediated endocytosis,
possibly through a number of non-specific trafficking routes
[128]. Its use as a targeting ligand therefore has provided a potential
practical approach to therapy, but also as a paradigm approach for
receptor-mediated targeting and intracellular drug-targeting.
Zhang et al. used folate-conjugated carboxylated and sulfonated
graphene to target the breast cancer cell line MCF-7, delivering
mixed anti-cancer drugs doxorubicin and camptothecin
bound to graphene [129]. The flakes were also conjugated with
Rhodamine-B and fluorescence microscopy images show the flakes
dispersed evenly through all the cells with no specific intracellular
localisation. This is compared to images of A549 lung epithelial cells
(on which folate receptors are not overexpressed), similarly treated
with the flake complexes, where very weak fluorescence is
observed in few cells. In addition, folate-conjugated flakes induced
significantly greater toxicity than non-targeted flakes at 20 lg/mL –
inducing a similar level of cytotoxicity as free DOX. These results
have been confirmed by other groups in a range of different
folate-receptor expressing cell lines such as HeLa [10] and HepG2
[40]. The transferrin receptor is similarly overexpressed by some
cancer cells, hence Sasidharan et al. used transferrin as a targeting
ligand conjugated to carboxylated graphene, which was introduced
to the cancer cell line K562. Further, the authors used graphene’s
sensitivity to radiofrequency (RF) radiation to induce localised
heating in a method similar to the more commonly used IR absorp-
tion mentioned above – selectively killing cancer cells, including
those resistant to existent chemotherapy drugs. The strong
response of graphene to RF is of particular importance due to its
increased tissue penetration depth in comparison with IR [130].
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cells or cellular organelles – in gene delivery this may be the
nucleus. Molecules with mass less than 40–45 kDa can diffuse pas-
sively through the nuclear pore complex; however, larger macro-
molecules need to be actively transported. The most well
understood mechanism for this is the classical nuclear import
cycle, a receptor-driven process in which a cytoplasmic carrier pro-
tein recognises macromolecules for import, binds first with the tar-
get protein, then the appropriate receptor in the nuclear pore
complex, at which point the trimeric complex translocates into
the nucleus [131]. The proteins that are to be transported into
the nucleus are recognised from the inclusion of a Nuclear Locali-
sation Signal (NLS) sequence in their structure [131–133]. Such
sequences have been incorporated into therapeutics delivery com-
plexes, including in graphene research, although the efficacy of this
process may be limited by cargo size [35]. In 2012 Ren et al. [15]
further non-covalently functionalised a GO-PEI complex with NLS
PV7 to increase the efficiency of the vehicle which was delivering
plasmid DNA (enhanced green fluorescent protein) [15]. The per-
centage quantitative transfection in both 293T and HeLa cells
was improved by up to around 7% and 20% respectively compared
to complexes that did not include the NLS sequence.
5.3. Cargo delivery
Achieving targeted drug-effect for a transported therapeutic
agent requires that it is effectively released at its site of action.
The mechanism required to release the drug depends on the gra-
phene preparation and method of linkage. For minimally function-
alised GFNs, cargo is generally bound by hydrophobic or p–p
interactions; these may be released following change to physico-
chemical properties within the environment, frequently making
use of changing physiological characteristics taking place within
the cell or competitive binding to ligand. Some of the first exam-
ples used changes in pH to alter bonding-affinity: DOX attached
by hydrogen bonding to GO may be released by localised pH
change within the cell [44]. In an adaptation of the same approach,
pH change within the extracellular microenvironment was used to
drive the controlled release of bioactive molecules outside of cells:
the inhibitory-antibody anti-IL10R and the interferon IFN! were
loaded directly onto graphene oxide flakes, both individually and
in combination, with the aim of facilitating the slow release of
the bound inhibitory-antibody and interferon within tissues to
modify an immune response [134]. The antibody was found to be
released in acidic environments but remain attached at neutral
pH. Exposure to the biomolecule-GO complexes both individually
and in combination was found to significantly increase the produc-
tion of interleukin 12-B, confirming the successful release of the
biomolecules.
For single stranded genetic material adsorbed to the basal plane
of GFNs it has been demonstrated that release is promoted by com-
petitive binding to the complementary nucleotide strand [4,5,135].
This process is believed also to underlie the observed release of an
oligodeoxyribozyme from native GO, which was used to cleave the
mRNA of Hepatitis C non-structural gene 3 (NS3) in a Hepatitis C
infected liver cell line [135]. In this case, the genetic material
was labelled with a fluorescein reporter (FAM), which was
quenched while bound to the flakes, so that cargo release was con-
firmed by the recovery of the fluorescence. The FAM label revealed
localisation of the deoxyribozyme in the perinuclear region, while
NS3 gene and protein down-regulation suggested that release was
associated with binding to NS3 mRNA [135].
For functionalised GFNs cargo delivery must be tailored to the
binding method used to attach the cargo as well as any specific
functionalisation methods employed to facilitate cell targeting [7,
15–17,23,112,125,129]. This may be illustrated by the use ofgraphene-conjugated PEI. This combination facilitates the binding
of genetic material such as siRNA to graphene [16], and through
its positive surface charge can promote cell entry, and importantly,
its unique properties can promote lysosomal escape through the
proton sponge effect. Once the complex has escaped the lysosome,
while no specific physical process is known to facilitate cargo
release from PEI, the continued condensation of genetic material
on the PEI-graphene complex may continue to protect it and facil-
itate its transport through the cytosol towards the nucleus. This
functionalisation may also carry negative effects since GO-PEI that
has not been further functionalised strongly interacts with serum
components, affecting both particle size and stability and reducing
the transfection efficiency [125]. The addition of PEG to GO-PEI has
been demonstrated to increase the stability of the flakes, and to
increase transfection efficiency in HELA cells. In this paper it was
found that linking this to photo-thermal effects based on the high
infrared absorption of GO further enhanced transfection efficiency:
from approximately 6% to around 25% presenting an opportunity
for localised delivery [125].
Several groups have encapsulated GFNs in hydrogels to pro-
mote the localised and controlled delivery of cargo, often leading
to significantly improved delivery profiles compared to the native
hydrogel [78,136–139]. Paul et al. [78] used a methacrylated gela-
tin (GelMA) hydrogel matrix, in which PEI-GO, loaded with a vas-
cular endothelial growth factor-165 (VEGF) plasmid (pDNA), was
embedded. The hydrogel was injectable allowing localised delivery
to the desired tissue and through chemical and physical tuning was
able to produce slow-release of the pDNA over a 72 h timescale.
The pro-angiogenic properties of the preparation were confirmed
in vitro using a rat heart myoblast model, where a 33% increase
in proliferation over the control groups was observed after 96 h.
Using a microchannel approach to mirror wound healing with
HUVEC cells, conditioned media from the experiment increased
in number and enhanced HUVEC migration around the microchan-
nel. Using a rat in vivo model of myocardial infarction, the fGO-
hydrogel increased capillary density and reduced scar tissue for-
mation with a significantly improved cardiac ejection fraction after
days 3 and 14 compared with control groups suggesting that the
system could promote the growth of vasculature following acute
myocardial infarction.
Other groups have worked to produce GFN therapeutics
delivery-vehicles that incorporate sustained release. Moore et al.
[23] coated GO flakes with PLA-PEG, where the PLA was used to
encapsulate and slowly release Paclitaxel (GrLP-PTX) to treat
glioblastoma. CNTs were used as a comparator and were similarly
functionalised (CLPs). Loading of cargo was much higher for gra-
phene, which was attributed to its very high surface area, and
release rates over the time course were slower. As shown in their
previous paper [106], the release of the PTX is far more rapid for
CLPs than for graphene flakes, with approximately 80% of the drug
released in the first 25 h, compared to 6% released from GrLP-PTX
in the first 20 h. Therefore, although the PTX is encapsulated within
the PLA in both graphene and CNT, the difference in shape between
CNTs and graphene may be a significant determinant of the release
profiles, as the curved CNT surface may result in more widely
spaced PLA brushes. This shows that while the GFNs are highly
functionalised, such that many of the inherent GFN properties
may be masked at the point of delivery, they can still make a sig-
nificant difference in terms of the efficacy of vehicle.6. Conclusion
Research into graphene’s use as a therapeutics delivery vehicle
has moved on to the point where increasingly highly function-
alised flakes are being used alone and in combination with other
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their individual aims. However the material itself is often still
poorly defined; the initial suspensions are often polydisperse and
preparation methods vary significantly between groups. In this
review it has been shown that all the physicochemical properties
of GFNs – both before and after functionalisation – can have a sig-
nificant impact on their interaction with the physiological environ-
ment and the tissues that reside there. This is relevant to both the
flake’s toxicity and its ability to deliver therapeutics effectively.
From the literature reviewed in this article, however, some ten-
tative conclusions may be found. In terms of geometry, flakes with
sub-micron lateral dimensions that are still larger than 20 nm may
invoke the least inflammatory and toxic responses and thin flakes
(ie few layer or less) are also less toxic, given appropriate function-
alisation. The flakes used should be appropriately functionalised:
pristine graphene and rGO are highly hydrophobic, but even with
mild surface functionalisation can still cause a significantly toxic
response; despite the hydrophilicity of GO, most groups have
found that the flakes need additional functionalisation to improve
stability, and depending on the functionalisation used, the resul-
tant flakes may be less toxic, immunogenic and thrombotic. An
improvement in stability will also reduce bioaccumulation; how-
ever, GFNs have been shown to undergo biodegradation in vitro
and in vivo – albeit over relatively long timescales. Mitigating the
effect of GFN flake functionalisation on biodegradation is also
important – as many of the materials used to improve circulation
time may also result in bioaccumulation due to increased resi-
dency time. The use of multiple low doses of GFNs, either through
repeated administration or by making use of technologies such as
hydrogels to promote slow release, may result in lower toxicity
and increased efficacy. With regard to delivery, although the EPR
effect may be relied upon to promote increased GFN accumulation
in tumour sites, for instance, making use of the flexibility in GFN
functionalisation, many groups have used active targeting methods
to direct the flakes to the point of action – both intracellularly and
extracellularly. In terms of therapeutics delivery, although initial
work focused on the use of GFNs’ intrinsic physicochemical prop-
erties to both load and release therapeutics such as small molecule
drugs or single stranded genetic material, increasingly flakes are
being further functionalised, eg with polymers, to allow attach-
ment and condensation of a greater range of therapeutics to be
delivered. Such functionalisation may also be used to improve
the flakes’ efficacy – although care should be taken that polymers
such as PEI that have been traditionally used in gene therapy, but
have not reached the clinic due to their unfavourable toxicological
profiles, are not depended on in GFN research – even if their
attachment to GFNs mitigates their toxicity somewhat.Acknowledgements
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